Bausch + Lomb (NYSE:BLCO) Issues Quarterly Earnings Results

Bausch + Lomb (NYSE:BLCO) posted its quarterly earnings data on Wednesday. The company reported $0.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.02, Zacks reports. Bausch + Lomb had a positive return on equity of 3.17% and a negative net margin of 7.86%. Bausch + Lomb updated its FY 2025 guidance to EPS.

Bausch + Lomb Stock Down 0.1 %

Shares of BLCO stock opened at $16.40 on Wednesday. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69. Bausch + Lomb has a 12 month low of $13.16 and a 12 month high of $21.69. The company has a 50 day simple moving average of $17.51 and a two-hundred day simple moving average of $18.16.

Wall Street Analysts Forecast Growth

BLCO has been the topic of several analyst reports. Needham & Company LLC reiterated a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 price objective on the stock. in a research report on Monday, December 2nd. Stifel Nicolaus cut their price objective on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating on the stock in a report on Wednesday, January 29th. Bank of America reiterated an “underperform” rating and set a $18.00 target price on shares of Bausch + Lomb in a report on Thursday, December 12th. Finally, Wells Fargo & Company cut their price target on Bausch + Lomb from $26.00 to $24.00 and set an “overweight” rating on the stock in a research note on Thursday, January 16th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat.com, Bausch + Lomb has an average rating of “Hold” and a consensus target price of $20.25.

About Bausch + Lomb

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.